In KRAS mutant cancers, endogenous TRAIL and its receptors have been highlighted to promote tumor growth and metastases by activating Rac1 and promoting migration and invasion of cancer cells, with a direct correlation seen between the level of expression of TRAIL-R2 and the extent of metastasis seen in patients [82,86,148,172]. The gene discussed is KRAS; the disease is cancer.